Venetia Zachariou

List of Publications by Year
in descending order

46 papers	3,372 citations	236925 25 h-index	302126 39 g-index
49 all docs	49 docs citations	49 times ranked	4230 citing authors

#	Article	IF	Citations
1	Targeting HDAC6 in the Dorsal Root Ganglia Attenuates Peripheral Nerve Injuryâ€induced Hypersensitivity. FASEB Journal, 2022, 36, .	0.5	0
2	A novel HDAC1/2 inhibitor alleviates physical and emotional symptoms associated with spontaneous oxycodone withdrawal in neuropathic pain mice. FASEB Journal, 2022, 36, .	0.5	0
3	Persistent SARSâ€CoVâ€2 Effects Induce Neuropathy Signature in Dorsal Root Ganglia Underlying Hypersensitivity in a Hamster Model. FASEB Journal, 2022, 36, .	0.5	0
4	SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Science Translational Medicine, 2022, 14, .	12.4	129
5	Comparative Transcriptional Analyses in the Nucleus Accumbens Identifies RGS2 as a Key Mediator of Depression-Related Behavior. Biological Psychiatry, 2022, 92, 942-951.	1.3	5
6	A Femaleâ€specific Role of RGS20 in Transcriptional, Epigenomic and Behavioral Responses to Chronic Pain. FASEB Journal, 2021, 35, .	0.5	0
7	Chronic painâ€mediated Regulator of G protein signaling 4 (RGS4) gene expression in superficial dorsal horn of spinal cord. FASEB Journal, 2021, 35, .	0.5	0
8	A promising chemical series of positive allosteric modulators of the Î¼-opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects. Neuropharmacology, 2021, 195, 108673.	4.1	16
9	Striatal Rgs4 regulates feeding and susceptibility to diet-induced obesity. Molecular Psychiatry, 2020, 25, 2058-2069.	7.9	14
10	The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities. Biological Psychiatry, 2020, 87, 64-73.	1.3	132
11	HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice. Psychopharmacology, 2020, 237, 2139-2149.	3.1	19
12	Regulators of G Protein Signaling in Analgesia and Addiction. Molecular Pharmacology, 2020, 98, 739-750.	2.3	17
13	Microglia and macrophages promote corralling, wound compaction and recovery after spinal cord injury via Plexin-B2. Nature Neuroscience, 2020, 23, 337-350.	14.8	146
14	RGS4 Maintains Chronic Pain Symptoms in Rodent Models. Journal of Neuroscience, 2019, 39, 8291-8304.	3.6	23
15	<scp>RGS</scp> 9â€2 rescues dopamine D2 receptor levels and signaling in <i> <scp>DYT</scp> 1 </i> dystonia mouse models. EMBO Molecular Medicine, 2019, 11, .	6.9	44
16	Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines, 2019, 7, 97.	3.2	161
17	Oxycodoneâ€induced gene expression adaptations in the brain reward center in a murine model of neuropathic pain. FASEB Journal, 2019, 33, 808.19.	0.5	0
18	Targeting RGSz1 actions in the periaqueductal gray promotes opioid analgesia and decreases reward sensitivity. FASEB Journal, 2019, 33, 498.7.	0.5	2

#	Article	IF	Citations
19	Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/Î²-catenin pathway. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2085-E2094.	7.1	26
20	RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States. Neuropsychopharmacology, 2017, 42, 1548-1556.	5.4	24
21	Brain-Derived Neurotrophic Factor in the Mesolimbic Reward Circuitry Mediates Nociception in Chronic Neuropathic Pain. Biological Psychiatry, 2017, 82, 608-618.	1.3	75
22	Neuropathic pain promotes adaptive changes in gene expression in brain networks involved in stress and depression. Science Signaling, 2017, 10, .	3.6	128
23	Effective Attenuation of Adenosine A1R Signaling by Neurabin Requires Oligomerization of Neurabin. Molecular Pharmacology, 2017, 92, 630-639.	2.3	2
24	Microbiota-driven transcriptional changes in prefrontal cortex override genetic differences in social behavior. ELife, 2016, 5, .	6.0	226
25	Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience, 2016, 338, 81-92.	2.3	122
26	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	1.3	2
27	Rodent models of treatment-resistant depression. European Journal of Pharmacology, 2015, 753, 51-65.	3.5	44
28	Epigenetic mechanisms of chronic pain. Trends in Neurosciences, 2015, 38, 237-246.	8.6	273
29	RGS9-2â€"controlled adaptations in the striatum determine the onset of action and efficacy of antidepressants in neuropathic pain states. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5088-97.	7.1	32
30	RGS9-2 modulates sensory and mood related symptoms of neuropathic pain. Neurobiology of Learning and Memory, 2014, 115, 43-48.	1.9	20
31	Nucleus Accumbens-Specific Interventions in RGS9-2 Activity Modulate Responses to Morphine. Neuropsychopharmacology, 2014, 39, 1968-1977.	5.4	36
32	Regulator of G protein signaling 4 is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8254-8259.	7.1	73
33	R7BP Modulates Opiate Analgesia and Tolerance but not Withdrawal. Neuropsychopharmacology, 2012, 37, 1005-1012.	5.4	18
34	RGS9-2 modulates nociceptive behaviour and opioid-mediated synaptic transmission in the spinal dorsal horn. Neuroscience Letters, 2011, 501, 31-34.	2.1	13
35	A Unique Role of RGS9-2 in the Striatum as a Positive or Negative Regulator of Opiate Analgesia. Journal of Neuroscience, 2011, 31, 5617-5624.	3.6	59
36	Brain Region Specific Actions of Regulator of G Protein Signaling 4 Oppose Morphine Reward and Dependence but Promote Analgesia. Biological Psychiatry, 2010, 67, 761-769.	1.3	62

#	Article	IF	Citations
37	Chapter 10 Regulators of G Protein Signaling in Neuropsychiatric Disorders. Progress in Molecular Biology and Translational Science, 2009, 86, 299-333.	1.7	30
38	RGS9-2: probing an intracellular modulator of behavior as a drug target. Trends in Pharmacological Sciences, 2009, 30, 105-111.	8.7	38
39	Distinct Roles of Adenylyl Cyclases 1 and 8 in Opiate Dependence: Behavioral, Electrophysiological, and Molecular Studies. Biological Psychiatry, 2008, 63, 1013-1021.	1.3	62
40	Multiple Actions of Spinophilin Regulate Mu Opioid Receptor Function. Neuron, 2008, 58, 238-247.	8.1	65
41	RGS9â€2 differentially regulates adenylyl cyclase signaling by opioid and cannabinoid receptors in the mouse CNS. FASEB Journal, 2008, 22, 712.10.	0.5	0
42	RGS9â€2 is a negative modulator of Î¼â€opioid receptor function. Journal of Neurochemistry, 2007, 103, 617-625.	3.9	61
43	An essential role for Î”FosB in the nucleus accumbens in morphine action. Nature Neuroscience, 2006, 9, 205-211.	14.8	237
44	RGS9 Modulates Dopamine Signaling in the Basal Ganglia. Neuron, 2003, 38, 941-952.	8.1	245
45	Essential role for RGS9 in opiate action. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13656-13661.	7.1	229
46	CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11435-11440.	7.1	447